Table 2.
Participants progressing to severe COVID-19 illness.
| Treatment Group | Age Group | Sex | BMI | Viral Load1 Day 1/Day 4 | Comorbidities | Study Day | Medical Attention Required | Secondary Diagnosis | SpO2 |
|---|---|---|---|---|---|---|---|---|---|
| NTZ | 70–80 | M | 25·5 | 7·39 / 4·79 | Hypertension, coronary artery disease, atrial fibrillation, bilateral iliac stents, type 2 diabetes mellitus, peripheral vascular disease, hyperlipidemia, decreased renal function, cholecystectomy, prostate cancer with prostatectomy, hypogonadism, gout | 5 | Hospitalized | COVID-19 pneumonia | 91% |
| Placebo | 70–80 | M | 31·7 | 6·18 / ≥7·40 | Type 2 diabetes mellitus, Parkinson's disease, neuropathy, colon cancer/colon re-sectioning, benign prostatic hyperplasia, obesity | 7 | Hospitalized | COVID-19 pneumonia | 88% |
| Placebo | 60–70 | F | 36·4 | 6·54 / 7·06 | Hyperlipidemia, osteoarthritis, insomnia, anxiety, obesity | 10 | Emergency room | COVID-19 pneumonia | 93% |
| Placebo | 60–70 | M | 33·0 | ND / ND | Hypertension, hypercholesterolemia, pre-diabetes, gastroesophageal reflux disease, osteoarthritis, anxiety, prostate cancer and surgery, bilateral hip arthroplasty, cataracts, obesity | 7 | Hospitalized | Dyspnea | 88% |
| Placebo | 50–60 | M | 34·9 | 6·47 / ND | Hypertension, elevated liver enzymes, previous stroke, subcarinal adenopathy, migraines, nerve issues due to injury, obesity | 7 | Hospitalized | COVID-19 pneumonia | 90% |
| Placebo | 50–60 | M | 26·8 | ≥7·40 / NC | Type 2 diabetes mellitus, borderline reduced kidney function, coronary artery disease, coronary artery bypass graft, neuropathy, hypothyroidism, hernias | 9 | Hospitalized | COVID-19 pneumonia | 84% |
| Placebo | 50–60 | F | 22·8 | 5·96 / ≥7·40 | Hypertension, anxiety, migraine headaches, cigarette use | 3 | Hospitalized | Syncope | 93% |
| Placebo | 30–40 | M | 35·4 | ≥7·40 / IND | Essential hypertension, elevated liver enzymes, asthma, obesity | 5 | Clinic visit | Asthma (exacerbation) | 93% |
1
log10 RNA copies/mL, upper limit of quantitation of the assay was 7·40 log10 RNA copies/mL.
2ND = Not Done due to insufficient sample; NC = Sample Not Collected (visit missed), IND = Indeterminate result by RT-PCR.